RE:No path forward to $3 without ditching Nash & Oncology Bravo!!!
Great post and to the point! Exactly the reality for TH and us shareholders!
Good luck
PWIB123 - (3/2/2023 8:47:08 PM)
No path forward to $3 without ditching Nash & Oncology
I don't see how $THTX will ever climb back to $3 without slashing expenses, getting cash flow positive, and eliminating their aspiring drug programs. That is unless they have a real partner step up now. The company could barely trade at $3 before it had all the negative announcements and with the promise of the potential new drugs. The market has always discounted the stock. No way it will climb back that way without a complete corporate overhaul or some unexpected new announcement. The company's share price has been severely discounted due to the repeated missed expectations and significant increase in risk. Now we are seeing further dilution and leverage with no clear plan in place other than wait and see. We are waiting on a NASH partner. We are waiting to see if TH-1902 will resume. All signs point toward yes, but there's no clear explanation in my mind on how this will be done other than now we are looking for another partner. Our leadership team has backed us into a corner with no way out other than a hero to come alongside and help. I do find it interesting that the institutional players bought deeper. Marathon saw the opportunity for a power grab, because THTX has no leverage...at all. Sales are growing. So what? No one cares in terms of a higher share price, because of the risk profile the company now has. I think we stay at these depressed share price levels until the company offloads Oncology and slashes expenses or finds a genuine partner that brings significant resources to the equation. In my opinion, THTX is giving us no reason to continue holding. They've cried wolf too many times. I don't trust them. The market has signaled it doesn't trust them